Shanghai Escugen Biotechnology Co., Ltd

This study tested a new drug called ESG401 in people with advanced solid tumors that had spread or couldn't be removed by surgery. The main goals were to find a safe dose and see if the drug could shrink tumors. The trial included 156 people with various cancers including breast,…

This early-stage study tested a new antibody drug called ESG206 in adults with advanced B-cell cancers that had stopped responding to standard treatments. The main goal was to find a safe dose by giving small groups of patients increasing amounts of the drug and closely monitorin…